NeuroSense Therapeutics Ltd. NRSN
Regular-session close
After hours · Nov 13, 4:00 PM ET
- YTD
- -89.01%
- 1 year
- -90.80%
- Market cap
- 3.21M
- EPS (ttm)
- -47.10
- Shares out
- 23.13M
- Forward P/E
- -2.27
- YTD return
- -89.01%
- 1-year return
- -90.80%
- Volume
- 18.16K
- Avg volume
- 32.59K
- Open
- 1.77
- Previous close
- 1.76
- Day's range
- 1.60 – 1.78
- 52-week range
- 1.10 – 25.40
- Beta
- 1.56
- Analysts
- Buy
- Price target
- 7.50 (+343.8%)
5D +0.61 (+44.53%)
Key statistics
- Enterprise value
- 19.41M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.63M
- Total cash
- 1.21M
- Total debt
- 36.00K
- Return on equity
- 0.00%
- Short % of float
- 1.84%
- 50-day average
- 1.13
- 200-day average
- 1.16
Fundamental scorecard
5 of 25 checks passed on NRSN’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 18, 2024 | Sep 1, 2024 | 0.00 | -0.11 | — | — |
| Jun 24, 2024 | Mar 1, 2024 | 0.00 | -0.35 | — | — |
| Apr 5, 2024 | Dec 1, 2023 | 0.00 | -0.16 | — | — |
| Nov 28, 2023 | Sep 1, 2023 | 0.00 | 0.10 | — | — |
| Aug 16, 2023 | Jun 1, 2023 | 0.00 | -0.44 | — | — |
| Jun 1, 2023 | Mar 1, 2023 | 0.00 | -0.33 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | Maxim Group | down | Buy | Hold |
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- neurosense-tx.com
News
NeuroSense Adds New Data To PrimeC Application, Delays Health Canada Filing To March 2027
HC Wainwright & Co. Downgrades NeuroSense Therapeutics to Neutral
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib
12 Health Care Stocks Moving In Tuesday's After-Market Session NeuroSense Therapeutics Announces Nasdaq Hearings Panel Date Of November 10; Minimum Bid Price Compliance Already Regained; Sees PrimeC Milestones In December And Q1 2027
SpaceX, Qualcomm and 3 Stocks to Watch Heading Into Monday NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal
HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52
Your note
Sign in to keep a note on NRSN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cantor Fitzgerald, L.P. | 0.34% | 79,492 | 99.36K | Sep 29, 2024 |
| Xtx Topco Ltd | 0.20% | 45,996 | 57.49K | Sep 29, 2024 |
| Meitav Investment House Ltd. | 0.17% | 40,000 | 50.00K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.15% | 34,280 | 42.85K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.05% | 12,625 | 15.78K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.05% | 11,963 | 14.95K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 11,963 | 14.95K | Oct 30, 2024 |
